Sign In
Buy AKBA
$0.97
+0.0333 (+3.56%)
At Close: Jun 03, 2026
US$17.13 - That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These Results
06:15pm, Thursday, 07'th May 2020
As you might know, Akebia Therapeutics, Inc. (NASDAQ:AKBA) just kicked off its latest quarterly results with some very...
Akebia Shares Climb on Positive Anemia Drug Study Results
03:24pm, Thursday, 07'th May 2020
Company hits 52-week high of $12.25 Continue reading...
OPKO Health, Inc. (OPK) CEO Dr. Phillip Frost on Q1 2020 Results - Earnings Call Transcript
02:52am, Thursday, 07'th May 2020
Call end: 17:12 OPKO Health, Inc. (NASDAQ:OPK) Q1 2020 Earnings Conference Call May 6, 2020 4:30 PM ET Company Participants Yvonne Briggs - LHA IR Phillip Frost
Akebia Shares Climb on Positive Anemia Drug Study Results
12:00am, Thursday, 07'th May 2020Akebia Spikes 38% On Pivotal Trial Readout; And Further Upside Lies Ahead
05:49am, Wednesday, 06'th May 2020
Biopharma Akebia Therapeutics (AKBA) skyrocketed 38% in Tuesday’s trading after reporting positive topline data from the global Phase 3 clinical trials of vadadustat.This is the company’s investig
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
12:00am, Wednesday, 06'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs May 5)
• Adverum Biotechnologies...
Akebia Therapeutics Inc (AKBA) Q1 2020 Earnings Call Transcript
10:00pm, Tuesday, 05'th May 2020
AKBA earnings call for the period ending March 31, 2020.
Why Akebia Therapeutics Stock Is Crushing It Today
03:50pm, Tuesday, 05'th May 2020
Shares of Akebia Therapeutics (NASDAQ: AKBA) were skyrocketing 37.3% higher as of 11:25 a.m. EDT on Tuesday. The huge jump came after the biotech announced positive results from a late-stage clinical
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates
01:45pm, Tuesday, 05'th May 2020
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 25.40% and 14.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Akebia Therapeutics Q1 Earnings
01:38pm, Tuesday, 05'th May 2020
Shares of Akebia Therapeutics (NASDAQ:AKBA) surged 24% after the company reported Q1 results.Quarterly Results Earnings per share fell 6.82% year over year to ($0.47), which beat the estimate of ($0.6
Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced positive top-line results from INNO2VATE, its global Phase 3 cardiovascular outcomes program evaluating the efficacy and safety of vadadustat,
Akebia's shares jump on late-stage clinical trial results for kidney disease drug
11:21am, Tuesday, 05'th May 2020
Shares of Akebia Therapeutics Inc. gained 30% in premarket trading on Tuesday after the drugmaker reported positive topline results from a Phase 3 trial for patients with chronic kidney disease. The
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 5.)
Arcturus Therapeutics Ltd (...
